UCP2 and colorectal carcinoma: Immunohistochemical (IHC) analysis (Fig. 3B) was used for representative staining of CRC tissue samples from patients with poor responses to cetuximab treatment, with the results revealing elevated expression levels of FABP4, EGFR, and UCP2.